{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:28:19Z","timestamp":1784204899582,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) is a polyradiculoneuropathy mediated by the immune system and is the primary reason for acute flaccid paralysis. Intravenous immunoglobulin (IVIg) is a recognized immunotherapeutic drug that can accelerate recovery from GBS. Limited literature exists concerning cerebral infarction complications with IVIg following its use in the treatment of GBS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A patient was diagnosed with the acute inflammatory demyelinating polyradiculoneuropathy subtype of GBS, while another patient was diagnosed with the acute bulbar palsy variant of GBS 2 years prior and experienced a relapse of GBS. Both patients received immunoglobulin therapy, during which multiple acute cerebral infarctions were detected using magnetic resonance imaging. Both patients had a history of coronary artery atherosclerotic heart disease and vertebral artery stenosis, and D-dimer and fibrinogen degradation products were significantly elevated after immunoglobulin therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The risk of cerebral infarction associated with IVIg is generally low in patients with different GBS variants. Nevertheless, the occurrence of cerebral infarction associated with IVIg might not be insignificant in older patients with vascular risk factors and should be carefully monitored.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1433240","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T04:32:05Z","timestamp":1721709125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple cerebral infarctions after intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: two case reports and review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Weisen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002256","article-title":"Acute bulbar palsy as a variant of Guillain\u2013Barr\u00e9 syndrome","volume":"86","author":"Kim","year":"2016","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2019.15.3.404","article-title":"Recurrent Guillain\u2013Barr\u00e9 syndrome with anti-GT1a and anti-GQ1b ganglioside antibodies","volume":"15","author":"Hwang","year":"2019","journal-title":"J Clin Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2212163","article-title":"Therapeutic issues in Guillain\u2013Barr\u00e9 syndrome","volume":"23","author":"Magy","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.24358","article-title":"Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs","volume":"91","author":"Ammann","year":"2016","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008742","article-title":"Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.1.257","article-title":"Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis","volume":"42","author":"Silbert","year":"1992","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.6.790","article-title":"Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome","volume":"68","author":"Turner","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/jscd.2001.123772","article-title":"Cerebral infarction following intravenous immunoglobulin therapy for Guillain-Barre syndrome","volume":"10","author":"Velio\u011flu","year":"2001","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.3.458","article-title":"Neuropathologic findings in a Guillain\u2013Barr\u00e9 patient with strokes after IVIg therapy","volume":"59","author":"Byrne","year":"2002","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1051228404273820","article-title":"Reversible posterior leukoencephalopathy, cerebral vasoconstriction, and strokes after intravenous immune globulin therapy in Guillain-barre syndrome","volume":"15","author":"Doss-Esper","year":"2005","journal-title":"J Neuroimaging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.73768","article-title":"Stroke after intravenous gamma globulin","volume":"58","author":"Saeed","year":"2010","journal-title":"Neurol India"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-100","article-title":"Cerebral infarction 3 weeks after intravenous immunoglobulin for Miller Fisher syndrome: a case report","volume":"8","author":"Chang","year":"2014","journal-title":"J Med Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.034","article-title":"Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome\/Bickerstaff brain stem encephalitis overlap syndrome","volume":"23","author":"Stetefeld","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B16","article-title":"Guillain-Barre syndrome, and cerebral infarction: a case of rare complication","volume":"23","author":"Prateek","year":"2019","journal-title":"Indian J Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2021.06.021","article-title":"Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders","volume":"90","author":"Chun","year":"2021","journal-title":"J Clin Neurosci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-5013-z","article-title":"Adverse effects of treatment with intravenous immunoglobulins for neurological diseases","author":"Wittstock","year":"2006","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-328881","article-title":"IVIg-exposure and thromboembolic event risk: findings from the UK Biobank","volume":"93","author":"Kapoor","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case-control study of thromboembolic events associated with IV immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1096-8652","article-title":"Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations","volume":"65","author":"Wolberg","year":"2000","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000008040","article-title":"High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy","volume":"41","author":"Sztajzel","year":"1999","journal-title":"Eur Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.04.029","article-title":"Should we prevent thrombosis related to intravenous immunoglobulin infusions with systematic anticoagulant prophylaxis","volume":"177","author":"Arcani","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2012.07754.x","article-title":"Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways","volume":"122","author":"Widiapradja","year":"2012","journal-title":"J Neurochem"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.326","article-title":"Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke","volume":"4","author":"Fann","year":"2013","journal-title":"Cell Death Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1433240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T04:32:08Z","timestamp":1721709128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1433240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2024.1433240"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1433240","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"article-number":"1433240"}}